Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: EnQuest falls on production output warning

Thu, 02nd Sep 2021 10:55

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

----------

SMALL-CAP - WINNERS

----------

Tiziana Life Sciences PLC, up 18% at 72.35 pence, 12-month range 46.44p-206.00p. The clinical stage biotechnology company alongside US peer Precision BioSciences announce an exclusive license agreement to evaluate Tiziana's Foralumab, an anti-CD3 monoclonal antibody in conjunction with allogeneic CAR T candidates for cancer treatment. The companies would explore Foralumab as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy. Under the terms, Tiziana will receive upfront payment, certain milestone payments, and royalties for Foralumab.

----------

Gym Group PLC, up 3.4% at 292.58 pence, 12-month range 116.00p-317.50p. The no-frills gym chain reports rise in membership as restrictions ease. For the six months ended June 30, pretax loss barely narrows to GBP28.5 million from GBP28.6 million the year before, as administrations costs remain high at GBP54.6 million, and revenue declines 21% to GBP29.3 million from GBP37.3 million. However, membership numbers at the end of June rose to 730,000 from 698,000 a year prior. Looking ahead, membership numbers at the end of August dipped to 721,000 from June, but sees higher membership levels in September and October as students return to universities. "Despite the significant disruption caused by the pandemic, Gym Group is well placed to continue its steady recovery and plans for growth as it capitalises on a return to more normal activity," says Edison analyst Richard Finch.

----------

SMALL-CAP - LOSERS

----------

EnQuest, down 7.7% at 23.30p, 12-month range 8.67p-26.95p. The oil and gas firm reports narrowed first half loss, but warns full-year production will be at the lower end of the guidance range. For six months to June 30, its profit after tax narrowed to USD56.4 million from a USD472.4 million loss last year. Looking ahead, EnQuest sees 2021 average net production at the lower end of the guidance range of 46,000 barrels of oil equivalent per day and 52,000 boepd. This reflects expected performances at Magnus, the Greater Kittiwake Area and PM8/Seligi over the course of the second half of the year, it says.

----------

SDCL Energy Efficiency Income Trust PLC, down 3.7% at 113.17p, 12-month range 104.50p-119.00p. The investment company intends to raise GBP175 million via a share issue at 110.50p each, which is 6.0% discount to Wednesday's closing share price of 117.50p.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
18 Nov 2020 15:11

UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares

UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares

Read more
11 Nov 2020 20:17

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

Read more
2 Nov 2020 18:14

IN BRIEF: Tiziana To Start Brazil Clinical Trial For Covid-19 Patients

IN BRIEF: Tiziana To Start Brazil Clinical Trial For Covid-19 Patients

Read more
29 Oct 2020 16:04

Court gives Tiziana capital reduction the nod

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Thursday that the capital reduction required for the demerger of StemPrintER Sciences, and to enable the ultimate allotment of Accustem Sciences shares to its shareholders, has been sanctioned by the court.

Read more
30 Sep 2020 12:18

UK EARNINGS SUMMARY: City Pub In Signs Of Recovery After Tough Interim

UK EARNINGS SUMMARY: City Pub In Signs Of Recovery After Tough Interim

Read more
25 Sep 2020 16:05

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Sep 2020 15:51

IN BRIEF: Tiziana To Kick Off Clinical Study On Foralumab

IN BRIEF: Tiziana To Kick Off Clinical Study On Foralumab

Read more
16 Sep 2020 11:55

Tiziana Plans 2020 London IPO Of StemPrintER, SPARE Assets

Tiziana Plans 2020 London IPO Of StemPrintER, SPARE Assets

Read more
24 Aug 2020 14:33

IN BRIEF: Tiziana Life Sciences Gets US Patent On TZLS-501 In Covid-19

IN BRIEF: Tiziana Life Sciences Gets US Patent On TZLS-501 In Covid-19

Read more
24 Aug 2020 14:19

Tiziana gets US patent for 'TZLS-501' antibody

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that the United States Patent and Trademark Office (USPTO) has granted a patent for methods and use of fully human monoclonal antibody 'TZLS-501' that recognised both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.

Read more
21 Aug 2020 09:34

Tiziana Life Sciences Gets US Patent For Milciclib In Cancer

Tiziana Life Sciences Gets US Patent For Milciclib In Cancer

Read more
18 Aug 2020 18:36

IN BRIEF: Tiziana Gets US Patent For Foralumab As Crohn's Treatment

IN BRIEF: Tiziana Gets US Patent For Foralumab As Crohn's Treatment

Read more
5 Aug 2020 22:03

UK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination

UK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination

Read more
4 Aug 2020 19:16

UK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic

UK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic

Read more
4 Aug 2020 11:07

Tiziana inks four deals for development of Covid-19 treatment

(Sharecast News) - Biotechnology company Tiziana Life Sciences has signed agreements with four contract research organisations, it announced on Tuesday, to expedite the clinical development of 'TZLS-501' - a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for the treatment of Covid-19 patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.